SynthesisScientific reports2025
Impact of tumor necrosis factor-alpha gene variant in pediatric nephrotic syndrome: a meta-analysis.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to explore the risk associated with the Tumour Necrosis Factor-Alpha (TNFα)-308 G/A (rs1800629) gene polymorphism in relation to Childhood Nephrotic Syndrome (NS). The primary goal of the meta-analysis was to investigate the relationship between Nephrotic Syndrome and the TNFα 308 G/A [rs1800629] polymorphism of the cytokine gene. We conducted a systematic search across electronic databases like PubMed and Google Scholar to collect data from five distinct case-control studies focused on the TNFα 308 G/A gene variant, covering the period from 2010 to 2022. By aggregating allele and genotype frequencies from these studies, we computed the 95% confidence interval of odds ratio [OR] to assess the strength of the association. To evaluate heterogeneity and potential publication bias in the selected studies, Stats Direct software was employed. The sample size encompassed 1,560 individuals, including 628 cases and 932 controls from five separate case-control studies. The TNFα allele-A displayed significant heterogeneity [I²=80%, 95% CI] when compared to the G allele, and a statistically significant pooled OR of 2.32 [P = 0.0056*] was observed. In the overall analysis, no significance association was found in the dominant model [P = 0.068], but a significant association was detected in the recessive model [P = 0.0096*]. Consistent findings were observed in the co-dominant model, where both AA vs. GG [P = 0.0075*] and GA vs. GG [P = 0.0219*] showed significant associations. These results suggest a potential increase in the risk of the disease associated with the polymorphism of TNFα 308 G/A. The small number of studies, high heterogeneity (I² = 80%), and limited ethnic diversity may affect the robustness and generalizability of findings. Additionally, language bias and lack of confounder adjustment limit interpretability. The TNFα 308 G/A polymorphism was identified as being associated with the risk of developing childhood NS.Registration: Registered in PROSPERO with ID: CRD420251083425.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.